COVID-19 TESTING AVAILABLE

Ipsum Diagnostics Now Offering Testing for Monkeypox Virus

The MPX IDx assay is now available as monkeypox case counts continue to rise across the U.S.

Atlanta, GA – Ipsum Diagnostics LLC is now offering diagnostic testing for the monkeypox virus.

Ipsum’s MPX IDx assay, a real-time polymerase chain reaction (PCR) in vitro diagnostic test, is for the qualitative detection of monkeypox virus DNA (West African clade) and differentiation from other non-variola orthopoxviruses (NVOs). NVOs are not endemic in the United States and historically have been rare. However, since May 2022, monkeypox case counts have continued to rise across the country. As of July 15, 2022, a total of 1,814 cases have been identified nationwide, spanning 43 states and the District of Columbia.1

Test Ordering:
Ipsum’s MPX IDx assay is intended to confirm or rule out monkeypox virus in cases in which a healthcare provider considers
monkeypox virus to be a possible cause of a patient’s skin rash. The test is performed on a specimen (swab of the rash) taken from the patient and submitted by a healthcare provider. The expected turnaround time for MPX IDx testing is approximately 24 hours as measured from when the specimen is received in the laboratory.

Contact:
For more information about Ipsum’s MPX IDx testing, please send an email to: sales@ipsumdiagnostics.com.

About Ipsum Diagnostics:
Ipsum is a College of American Pathologists (CAP)-accredited laboratory specializing in molecular PCR pathogen detection.
Ipsum’s response to public health threats has achieved recognition since early 2020, when it became the first laboratory in Georgia to receive the FDA’s Emergency Use Authorization (EUA) for its COV-19 IDx® RT-PCR assay for SARS-CoV-2, the virus that causes COVID-19. Ipsum partnered with the Georgia Department of Public Health to provide PCR COVID-19 testing throughout the state. To date, Ipsum has performed more than 1.3 million COV-19 IDx® tests.

Disclaimer:
Ipsum is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high-complexity clinical laboratory testing. The MPX IDx assay was developed and its performance characteristics were determined by Ipsum Diagnostics LLC. The test is used for clinical purposes and should not be regarded as investigational or for research purposes.

The MPX IDx assay is designed to detect the monkeypox virus. It is not intended to specifically detect other orthopoxviruses.

1 Centers for Disease Control and Prevention, https://www.cdc.gov/poxvirus/monkeypox/response/2022/us-map.html (updated July 15, 2022).

Share this post